CASI Pharmaceuticals Inc

Company Profile

CASI Pharmaceuticals Inc had its IPO on 1996-06-12 under the ticker symbol CASI.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. CASI Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of CASI Pharmaceuticals Inc opened at $2.08 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.99 - $2.09, and closed at $1.99.

This is a -1.49% slip from the previous day's closing price.

A total volume of 14,557 shares were traded at the close of the day’s session.

In the last one week, shares of CASI Pharmaceuticals Inc have slipped by -0.5%.

CASI Pharmaceuticals Inc's Key Ratios

CASI Pharmaceuticals Inc has a market cap of $0.027 billion, indicating a price to book ratio of 0.396 and a price to sales ratio of 0.787.

In the last 12-months CASI Pharmaceuticals Inc’s revenue was $0.035 billion with a gross profit of $0.018 billion and an EBITDA of $-0.032 billion. The EBITDA ratio measures CASI Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CASI Pharmaceuticals Inc’s operating margin was -95.4% while its return on assets stood at -15.8% with a return of equity of -30.2%.

In Q2, CASI Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 19.7%.

CASI Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-2.257 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CASI Pharmaceuticals Inc’s profitability.

CASI Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.139 and a EV to EBITDA ratio of -0.153. Its price to sales ratio in the trailing 12-months stood at 0.787.

CASI Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

CASI Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

CASI Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

CASI Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, CASI Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, CASI Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$1.99

52-Week High

$11.5

52-Week Low

$1.84

Analyst Target Price

$22.67

CASI Pharmaceuticals Inc stock is currently trading at $1.99 per share. It touched a 52-week high of $11.5 and a 52-week low of $11.5. Analysts tracking the stock have a 12-month average target price of $22.67.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.